Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H22FN3O3 |
| Molecular Weight | 407.4375 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OCC2(N)CC2)C=C3N=CC=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1
InChI
InChIKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
| Molecular Formula | C23H22FN3O3 |
| Molecular Weight | 407.4375 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:14:01 UTC 2023
by
admin
on
Sat Dec 16 02:14:01 UTC 2023
|
| Record UNII |
GKF8S4C432
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
||
|
FDA ORPHAN DRUG |
576017
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB11885
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
SUB192810
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
C138997
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
100000177425
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
GKF8S4C432
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
ANLOTINIB
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | Anlotinib (AL3818) - MedKoo CAT NO.: 206058Description: Anlotinib, alos known as AL3818, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). (Last update: 7/2/2015). Synonym: AL3818, AL-3818, AL 3818, Anlotinib - IUPAC/Chemical Name: NONE | ||
|
LM-10
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
1058156-90-3
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
CHEMBL3545021
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
25017411
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY | |||
|
11077
Created by
admin on Sat Dec 16 02:14:01 UTC 2023 , Edited by admin on Sat Dec 16 02:14:01 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Results: Dose-limiting toxicities (DLT) at the 10mg/d for consecutive 4 weeks group was grade 3 hypertension, and significant accumulation of anlotinib was observed. For 2 weeks on/1 week off group, DLT were grade 3 hypertension and grade 3 fatigue at the dose of 16 mg/d, the maximum-tolerated doses (MTD) was 12mg/d, the plasma concentration of anlotinib was well controlled. Anlotinib reached its maximum plasma concentration with Tmax of 411 h after orally administration at 10, 12, or 16 mg/subject. Then it eliminated slowly with t1/2of 64136 h and MRT of 124167 h. 20 patients of the 21 patients at the dose of 12mg/d (2 weeks on/1 week off) were assessable for efficacy, 3 patients had a partial response(include renal cancer(n = 2), and soft tissue tumor),14 patients had stable disease(include medullary carcinoma of thyroid, NSCLC, colon cancer, melanoma, thymic carcinoma, and adenoid cystic carcinoma), with 9 patients lasting > 72 weeks. Official Title: A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics Purpose: Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug AdministrationSFDA which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis. Drug: Anlotinib(Primary); Indication: Renal cell carcinoma; Focus: Therapeutic Use; Sponsor: Chia Tai Tianqing Pharmaceutical Group; Most Recent Events: 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016., 25 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016., 22 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
|
